Mohammed N, Xiao EH, Mohsen S, Xiong Z, Zhou R#. PD-1/PD-L1 inhibitor treatment and its impact on clinical imaging in non-small cell lung cancer: a systematic review and meta-analysis of immune-related adverse events. Front Oncol. 2023 Sep 29;13:1191681. doi: 10.3389/fonc.2023.1191681. PMID: 37841435; PMCID: PMC10571717. (JCR2区 IF=6.24)
发布时间：2026-10-01
点击次数：
是否译文：否
上一条： Shi, W., Tanzhu, G., Chen, L., Ning, J., Wang, H., Xiao, G., Peng, H., Jing, D., Liang, H., Nie, J., Yi, M., Zhou R#. (2024). Radiotherapy in Preclinical Models of Brain Metastases: A Review and Recommendations for Future Studies. International Journal of Biological Sciences, 2024 Jan 1; 20(2), 765-783. doi: 10.7150/ijbs.91295. PMID: 38169621. (JCR1区 IF=11.7)
下一条： Tian W, Niu L, Wang Z, Lu R, Xiao G, Deng F, Tanzhu G, Zhou R#. Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States. Front Immunol. 2023 Sep 26;14:1268070. doi: 10.3389/fimmu.2023.1268070. PMID: 37822936 (JCR1区 IF=8.79)